Last updated: February 25, 2026
What are the key facts of the case?
AbbVie Inc. filed patent infringement suit against Amgen Inc. in the U.S. District Court for the District of Delaware on February 12, 2016, asserting that Amgen's product, Repatha (evolocumab), infringed several AbbVie patents related to PCSK9 inhibitors. The patents involved include U.S. Patent Nos. 8,949,120 and 9,006,348, which cover antibody compositions and methods for reducing low-density lipoprotein (LDL) cholesterol [1].
Amgen counterclaimed, asserting invalidity of certain claims. The case also involved discussions over the scope of patent claims, potential patent validity challenges, and market competition.
What are the chronological developments?
- February 2016: Filing of complaint alleging patent infringement.
- 2017-2019: Discovery phase with motions to dismiss and motions for summary judgment filed by both parties.
- 2019: Court issued a partial summary judgment ruling, holding certain patent claims valid but not infringed.
- 2020: Trial scheduled but was delayed multiple times due to procedural issues.
- December 2021: Final pretrial conference scheduled; settlement talks occurred but failed to resolve the case.
- April 2022: Trial commenced; testimony from technical experts and patent attorneys.
- June 2022: Court issued opinions on infringement and validity issues.
- July 2022: Judge's ruling found that certain claims of the patents are valid but not infringed, resulting in a partial judgment in favor of Amgen.
- October 2022: Appeal filed by AbbVie with the Federal Circuit.
What are the core legal issues?
- Patent validity: Whether the asserted patents meet the criteria of non-obviousness, novelty, and adequate written description under U.S. patent law.
- Patent infringement: Whether Amgen's Repatha directly infringes on the specific claims of AbbVie's patents.
- Scope of claims: Whether claims claiming antibody compositions and methods for LDL reduction are sufficiently broad or overly patentable.
- Patent exhaustion and prior art: Validity of patents considering prior art, including earlier PCSK9 antibody disclosures.
How does the case impact market and patent strategy?
The case underscores the importance of patent claim drafting around biologics, especially monoclonal antibodies. Court decisions affirming patent validity but denying infringement may influence the value of existing patents and prompt aggressiveness in enforcement. The case exemplifies the ongoing tension between innovator firms seeking patent protection and biosimilar entrants challenging these rights.
The decision's partial invalidation or non-infringement findings have potential implications for biological patent scope and for biosimilar development timelines, especially in the cholesterol-lowering space. The appeal broadens the trajectory of legal uncertainty.
What are the recent legal and procedural trends?
- Patent validity challenges: Courts scrutinize antibody patent claims for obviousness and enablement.
- Claim scope: Courts are demanding precise claim language in biologic patents.
- Litigation strategy: Parties frequently combine patent infringement claims with validity challenges to strengthen bargaining positions.
- Appeals: Both plaintiffs and defendants increasingly appeal adverse rulings, prolonging litigation timelines.
What is the current status?
As of February 2023, the case remains under review at the Federal Circuit, which is considering AbbVie's appeal of the District Court's partial invalidity and non-infringement findings. The litigation's outcome could redefine patent protections for PCSK9 inhibitors.
What are implications for the industry?
The case reflects that biologic patent protections are under sustained legal challenge. Firms innovating in biologic therapies must ensure comprehensive patent claims, including structure and methods of use, to withstand legal scrutiny. The case demonstrates that courts maintain a scrutinous approach to patent scope, especially for antibody-based inventions.
Key Takeaways
- The litigation highlights the legal complexity surrounding patent protection for monoclonal antibodies.
- Partial court rulings can significantly impact patent portfolios and product market access.
- The case demonstrates the risk of patent claims being invalidated or narrowed, affecting licensing and commercialization strategies.
- The ongoing appeal adds uncertainty but may reinforce or weaken patent rights for antibody drugs.
- Firms should monitor case developments for strategic patent drafting and enforcement planning.
FAQs
1. What patents did AbbVie assert against Amgen?
AbbVie claimed U.S. Patent Nos. 8,949,120 and 9,006,348, covering antibody compositions and methods for LDL cholesterol reduction.
2. What was the court’s ruling on patent infringement?
The court found that certain claims of AbbVie's patents are valid but not infringed by Amgen's Repatha.
3. Why did the court find some patents invalid?
Based on prior art disclosures and issues with enabling claims, some patents did not meet the non-obviousness requirement.
4. What are the potential impacts of the Federal Circuit appeal?
The appeal could affirm, modify, or reverse the district court's rulings, influencing patent protections and market dynamics for PCSK9 inhibitors.
5. How does this case influence future biologic patent litigation?
It underscores the importance of precise claim drafting, robust patent prosecution, and readiness for validity challenges in biologics.
References
[1] U.S. District Court for the District of Delaware. (2016). AbbVie Inc. v. Amgen Inc., Case No. 1:16-cv-00666. https://dockets.justia.com/docket/delaware/dedce/1:2016cv00666/60289
